Clexio Biosciences
About Clexio Biosciences
Clexio Biosciences is a clinical-stage pharmaceutical company dedicated to the development of novel treatments designed to deliver clinical benefits to patients through sophisticated integration of drugs and new technologies. We are currently working on the development of a rich portfolio of five novel programs for the treatment of pain, depression and other CNS indications. Clexio Biosciences was established in March 2018. Dexcel Pharma Technologies, Elisabeth Kogan, Menashe Levy and Elena Kagan are the Co-founders of Clexio.